title: TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.
abstract: The histone deacetylase inhibitor Trichostatin A (TSA) has previously been found to induce caspase activity in the human prostate cancer cell lines DU145 and LNCaP. TSA treatment resulted in the release of cytochrome c and Smac/DIABLO from mitochondria in DU145, and activation of caspase-9 in both cell lines. We concluded that TSA mediated its effect via the mitochondrial pathway. The aim of the current study was to determine how TSA initiated the caspase cascade. The results revealed that caspase-2 plays an important role in TSA-induced apoptosis. Inhibition of caspase-2 by siRNA or expression of caspase-2dn substantially decreased caspase activity after TSA treatment in both cell lines, siRNA caspase-2 also inhibited TSA-induced cell death. Caspase-2 acts upstream of caspase-8 and -9 and mediates mitochondrial cytochrome c release. Coimmunoprecipitation experiments show that caspase-2 formed protein complexes with RADD/RAIDD and PIDD. Together, these data indicate that caspase-2 initiates caspase cascade after TSA treatment and involves the formation of the PIDDosome.
authors.affiliation: Department of Pathology, The University of Iowa, Iowa City, Iowa 52242-1087, USA.
authors.forename: Agshin F
authors.initials: AF
authors.lastname: Taghiyev
authors.forename: Natalya V
authors.initials: NV
authors.lastname: Guseva
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Glover
authors.forename: Oskar W
authors.initials: OW
authors.lastname: Rokhlin
authors.forename: Michael B
authors.initials: MB
authors.lastname: Cohen
mesh_terms: D053420:CRADD Signaling Adaptor Protein / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D053143:Caspase 2 / Q000235:genetics / Q000378:metabolism*; D053181:Caspase 8 / Q000378:metabolism; D053453:Caspase 9 / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D045304:Cytochromes c / Q000378:metabolism; D053418:Death Domain Receptor Signaling Adaptor Proteins; D004789:Enzyme Activation / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D034741:RNA, Small Interfering / Q000235:genetics; D014162:Transfection
chemical_list: D053420:CRADD Signaling Adaptor Protein; C104252:CRADD protein, human; D002352:Carrier Proteins; D053418:Death Domain Receptor Signaling Adaptor Proteins; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C485896:PIDD1 protein, human; D034741:RNA, Small Interfering; C012589:trichostatin A; D045304:Cytochromes c; D053143:Caspase 2; D053181:Caspase 8; D053453:Caspase 9